Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Acquired by Swiss National Bank

Swiss National Bank increased its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 0.5% in the first quarter, Holdings Channel reports. The firm owned 55,000 shares of the medical research company’s stock after buying an additional 300 shares during the quarter. Swiss National Bank’s holdings in Bio-Rad Laboratories were worth $13,396,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GeoWealth Management LLC raised its position in Bio-Rad Laboratories by 342.9% in the fourth quarter. GeoWealth Management LLC now owns 93 shares of the medical research company’s stock worth $31,000 after acquiring an additional 72 shares in the last quarter. Curat Global LLC acquired a new position in shares of Bio-Rad Laboratories in the first quarter worth $34,000. Allworth Financial LP lifted its holdings in Bio-Rad Laboratories by 260.0% in the 1st quarter. Allworth Financial LP now owns 144 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 104 shares in the last quarter. Headlands Technologies LLC boosted its position in Bio-Rad Laboratories by 64.1% during the first quarter. Headlands Technologies LLC now owns 356 shares of the medical research company’s stock worth $87,000 after acquiring an additional 139 shares during the last quarter. Finally, Skylands Capital LLC acquired a new position in Bio-Rad Laboratories in the first quarter valued at $122,000. 65.24% of the stock is owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Price Performance

Shares of BIO opened at $287.06 on Friday. The business’s 50-day moving average is $249.96 and its 200-day moving average is $256.13. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.12 and a quick ratio of 3.67. The company has a market capitalization of $7.77 billion, a price-to-earnings ratio of 24.47 and a beta of 0.90. Bio-Rad Laboratories, Inc. has a fifty-two week low of $211.43 and a fifty-two week high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, July 31st. The medical research company reported $2.61 EPS for the quarter, beating analysts’ consensus estimates of $1.93 by $0.68. The firm had revenue of $651.60 million for the quarter, compared to the consensus estimate of $614.82 million. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%. The firm’s revenue was up 2.1% on a year-over-year basis. During the same period in the previous year, the firm posted $3.11 earnings per share. Equities research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on BIO shares. Wall Street Zen raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. UBS Group reduced their price target on Bio-Rad Laboratories from $355.00 to $310.00 and set a “buy” rating for the company in a report on Friday, May 2nd. Royal Bank Of Canada upped their target price on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an “outperform” rating in a research note on Friday, August 1st. Citigroup decreased their price objective on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a “buy” rating for the company in a report on Friday, May 2nd. Finally, Wells Fargo & Company upped their target price on Bio-Rad Laboratories from $245.00 to $265.00 and gave the company an “equal weight” rating in a report on Friday, August 1st. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Bio-Rad Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $333.50.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.